Company / Operating Cash Flow
Dare Bioscience, Inc. Operating Cash Flow History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$5.5M
FY2025
5-year range
-$38.9M / $5.5M
FY2021-FY2025
Trend
+114.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 7 years, ranging from -$39M in FY2024 to $5M in FY2025.
Based on SEC 10-K filings.
$5M in FY2025.
Improved from -$18M to $5M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 114.1% year-over-year.
- Lowest operating cash flow in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -2.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.5M | +114.1% |
| FY2024 | -$38.9M | -114.8% |
| FY2023 | -$18.1M | +37.1% |
| FY2022 | -$28.8M | -50.9% |
| FY2016 | -$19.1M | -14.7% |
| FY2015 | -$16.6M | +20.9% |
| FY2014 | -$21.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026